A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

NCT03191786 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

453

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
DRUG: Vinorelbine
DRUG: Gemcitabine

Sponsor

Hoffmann-La Roche